Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib
Biologics
.
2015 Feb 19:9:23-4.
doi: 10.2147/BTT.S79507.
eCollection 2015.
Authors
Nathalie Bardy-Bouxin
1
,
Ewa Matczak
1
,
Geeta Devgan
1
,
Mabel Woloj
1
,
Mark Shapiro
1
Affiliation
1
Pfizer Oncology, Pfizer Inc., New York, NY, USA.
PMID:
25733805
PMCID:
PMC4340369
DOI:
10.2147/BTT.S79507
No abstract available